Boehringer Ingelheim Access to Healthcare Strategy 2025
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Search
The big, the bold, and the few
In the animal health industry, fewer players are vying for bigger market shares. What does that mean for companies, veterinarians, and consumers?
Redefining mental health to enable people to thrive
At Boehringer Ingelheim, we aim to develop targeted treatment approaches that address specific symptoms in people living with mental illness.
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Ukraine Help: We fly, we bike, we accommodate
The solidarity for Ukraine from Boehringer Ingelheim employees is incredible. Equally impressive is their practical help.
Building Lasting Partnerships for a Better Future
Working with the University of Georgia, we’ve co-created a sustainability training initiative that benefits people, animals and the planet.
Submit your animal health partnering opportunity
Information on how to submit your animal health innovation opportunity direct to Boehringer Ingelheim’s partnering team
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Biopharmaceutical Contract Manufacturing | Bioxcellence | Boehringer Ingelheim
Meet BioXcellence - your trusted partner for top-quality biopharmaceutical development & manufacturing. Experience our world-class service. Contact us.
Patient Organizations
Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Partnering pet therapeutics
Learn more about our research focus and our most recent partnerships regarding pet therapeutics.
InPedILD_trial_enrollment
First patient enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Access to Health Care
Access to Health Care
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Access to Healthcare Strategy Innovation
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Expectations towards our business partners
We utilize an extensive network of international suppliers for procuring raw materials, intermediates, packaging materials, technical components and services to deliver our innovative medications worldwide.
Co-creation with Communities
Making More Health has launched co-creation projects in Asia, Africa, Europe and other localities around the world with top social entrepreneurs.
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
Algorithms to battle heartworm disease
Partnership with the University of Melbourne uses AI to develop new veterinary solutions for pets
Meet our team
Meet our team
Big hearts united to help animals in Ukraine
Veterinaries volunteer at the Polish-Ukrainian border to help welcome Refugees and their animals. Refugees don’t rest until their animals are safe.
Are combination therapies the answer to battling KRAS cancers?
Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal
Registration Microbial Expert Workshop
Connect with our microbial specialists in Boston
Fabio Paganini fostering inclusion & agility in AH
How employees are contributing to an inclusive culture at Boehringer Ingelheim.